To produce enough amounts of clinical-grade adenovirus vectors, GMP compliant cell banks and virus stocks need to be developed, and scalable production and purification methods need to be established. The use of adenovirus vectors as a gene therapy product not only depends on the availability of efficient and robust downstream processes but also on the establishment of analytical tools that can track the bioprocess, to determine the intermediates and/or to characterize the final adenoviral vector.
